

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

POLYPEPTIDE SEQUENCE OF HUMAN VIMENTIN

(GENBANK ACCESSION NO. P08670 (SEQ ID NO.1))

1 MTRSVSSSS YRMFGGPGT ASRPSSRSY VTTSTRYSL GSALRPSTSR SLYASSPGGV
61 YATRSSAVRL RSSVPGVRL QDSVDFSLAD AINTEFKNTR TNEKVELQEL NDRFANYIDK
121 VRFLEQQNKI LLAELEQLKG QGKSRLGDL Y EEEMRELRRQ VDQLTNDKAR VEVERDNLAE
181 DIMRLREKLQ EEMLQREEAE NTLQSFQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE
241 EIQELQAIQ EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE
301 AANRNNDALR QAKQESTEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN FAVEAANYQD
361 TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY RKLLEGEESR ISLPLPNFSS
421 LNLRETNLDS LPLVDTHSKR TFLIKTVETR DGQVINETSQ HHDDLE

FIG. 12A

FIG. 12B-1
FIG. 12B-2
FIG. 12B-3

FIG. 12B

FIG. 12B-1

NUCLEIC ACID SEQUENCE OF HUMAN VIMENTIN
(GENBANK ACCESSION NO. X56134 (SEQ ID NO.2))

```

1  CGCGCCACCG CGCGCGCCCA GGCCATCGCC ACCCTCCGCA GCCATGTCCA CCAGGTCCGT
61  GTCCTCGTCC TCCTACCGCA GGATGTTCCG CGGCCCGGGC ACCGCGAGCC GGCCGAGCTC
121 CAGCCGGAGC TACGTGACTA CGTCCACCCG CACCTACAGC CTGGGCAGCG CGCTGCGCCC
181 CAGCACCAAG CGCAGCCTCT ACGCCTCGTC CCCGGGGCGC GTGTATGCCA CGCGCTCCTC
241 TGCCGTGCGC CTGCGGAGCA GCGTGCCCGG GGTGCGGCTC CTGCAGGACT CGGTGGACTT
301 CTCGCTGGCC GACGCCATCA ACACCGAGTT CAAGAACACC CGCACCAACG AGAAGGTGGA
361 GCTGCAGGAG CTGAATGACC GCTTCGCCAA CTACATCGAC AAGTGCGCT TCCTGGAGCA
421 GCAGAAATAG ATCCTGCTGG CCGAGCTCGA GCAGCTCAAG GGCCAAGCA AGTCGCGCCT


```

481 GGGGGACCTC TACGAGGAGG AGATCGGGA GCTGCGCCGG CAGGTGGACC AGCTAACCAA
541 CGACAAAGCC CGCGTCGAGG TGGAGCGCGA CAACCTGGCC GAGGACATCA TGC GCCTCCG
601 GGAGAAATTG CAGGAGGAGA TGCTTCAGAG AGAGGAAGCC GAAAACACCC TGCAATCTTT
661 CAGACAGGAT GTTGACAATG CGTCTCTGGC ACGTCTTGAC CTTGAACGCA AAGTGGAATC
721 TTTGCAAGAA GAGATTGCCT TTTTGAAGAA ACTCCACGAA GAGGAAATCC AGGAGCTGCA
781 GGCTCAGATT CAGGAACAGC ATGTCCAAAT CGATGTGGAT GTTTCCAAGC CTGACCTCAC
841 GGCTGCCCTG CGTGACGTAC GTCAGCAATA TGAAGTGTG GCTGCCAAGA ACCTGCAGGA
901 GGCAGAAGAA TGGTACAAAT CCAAGTTTGC TGACCTCTCT GAGGCTGCCA ACCGGAACAA
961 TGACGCCCTG CGCCAGGCAA AGCAGGAGTC CACTGAGTAC CGGAGACAGG TGCAGTCCCT
1021 CACCTGTGAA GTGGATGCCC TTAAGGAAC CAATGAGTCC CTGGAACGCC AGATGCCGTGA
1081 AATGGAAGAG AACTTTGCCG TTGAAGCTGC TAACTACCAA GACACTATTG GCCGCCTGCA

FIG. 12B-2

1141 GGATGAGATT CAGAAATATGA AGGAGGAAAT GGCTCGTCAC CTTCGTGAAT ACCAAGACCT
1201 GCTCAATGTT AAGATGGCCC TTGACATTGA GATTGCCACC TACAGGAAGC TGCTGGAAGG
1261 CGAGGAGAGC AGGATTCTC TGCCCTCTTCC AAACCTTTCC TCCCTGAACC TGAGGGAAAC
1321 TAATCTGGAT TCACTCCCTC TGGTTGATAC CCACTCAAAA AGGACACTTC TGATTAAAGAC
1381 GGTGAAACT AGAGATGGAC AGGTTATCAA CGAAACTTCT CAGCATCAGC ATGACCTTGA
1441 ATAAAAATTG CACACACTCA GTGCAGCAAT ATATTACCAG CAAGAATAAA AAAGAAATCC
1501 ATATCTTAA GAAACAGCTT TCAAGTGCCT TTCTGCAGTT TTTCAGGAGC GCAAGATAGA
1561 TTTGGAATAG GAATAAGCTC TAGTTCTTAA CAACCGACAC TCCTACAAGA TTTAGAAAAA
1621 AGTTACAAC ATAATCTAGT TTACAGAAA ATCTGTGCT AGAATACTTT TTAAAAGGTA
1681 TTTTGAATAC CATTAAACT GCTTTTTTTT TTCCAGCAAG TATCCAACCA ACTTGGTTCT
1741 GCTTCAATAA ATCTTTGGAA AAACTA

FIG. 12B-3

Procedure for immunofluorescence (non-permeabilized cells)

Amplification kit used:
 TSA kit #2 with
 HRP-goat anti-mouse
 IgG and Alexa fluor 488
 tyramide from molecular
 probes T-20192

FIG. 13A


Procedure for immunofluorescence (permeabilized cells)

FIG. 13B




FIG. 14




FIG. 15




FIG. 16




FIG. 17B

Expt	MDA/mito (epitopes)	Kd (nM)	r2
1	2764751	10.4	0.95
2	3477797	5.9	0.97
3	1496035	2.5	0.98
4	2720065	3.2	0.97
5	2012848	6.7	0.97
Ave	2494299	5.7	
Std	761530	3.1	

FIG. 17A

cells	AVE	STD	Kd	R/S
MCF-7	9.1.E+03	8.8.E+03	nd	
MCF-7/AR	3.8.E+05	1.1.E+05	nd	41.2
MDA	6.3.E+05	1.6.E+05	9.3±2.8	
MDA/mito	2.5.E+06	7.6.E+05	5.7±3.1	4.0
SKOV3	7.4.E+05	3.7.E+05	nd	
SKOV/T320	1.2.E+06	2.0.E+05	nd	1.6
2008	4.1.E+04	2.2.E+04	nd	
2008/T320	8.3.E+04	1.3.E+04	nd	2.0

FIG. 17C




FIG. 18

